A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

Edward M. Wolin1; Barbara Jarzab2; Barbro Eriksson3; Thomas Walter4; Christos Toumpanakis5; Michael Morse6; Paola Tomassetti7; Matthias Weber8; David Fogelman9; John Ramage10; Donald Poon11; Jerry Huang12; Michelle Hudson12; Jiang Li12; Janice L. Pasieka13; Abakar Mahamat14; Fredrik Swahn15; John Newell-Price16; Was Mansoor17; and Kjell Öberg3

1Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA
2MSC Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
3Uppsala University Hospital, Uppsala, Sweden
4Hospices Civils de Lyon and Université Claude Bernard Lyon-Est, Lyon, France
5Royal Free Hospital, London, UK
6Duke University Medical Center, Durham, NC, USA
7Az. Osp. di Bologna Policl. S.Orsola-Malpighi Univ. degli Studi, Bologna, Italy
8Johannes Gutenberg-Universität Mainz, Mainz, Germany
9University of Texas MD Anderson Cancer Center, Houston, TX, USA
10Hampshire Hospitals NHS, Basingstoke, UK
11Raffles Hospital, Singapore & Duke-NUS Graduate Medical School, Singapore
12Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA
13Foothills Hospital, Calgary, Alberta, Canada
14Centre Hospitalier Universitaire de Nice Hôp. de l'Archet, Nice, France
15Karolinska Institute, Stockholm, Sweden
16Royal Hallamshire Hospital, South Yorkshire, UK
17Christie Hospital, Manchester, UK

Background: Pasireotide, a novel somatostatin analog (SSA) with a broader receptor binding profile than available SSAs (octreotide and lanreotide), was investigated in a phase 3 study (NCT00690430) for control of disease-related symptoms in patients with NET inadequately controlled by the maximum approved dose of available SSAs.

Methods: Patients (N=110) were randomized 1:1 to receive pasireotide LAR (P; 60 mg IM) or octreotide LAR (O; 40 mg IM) every 28 days and stratified by predominant symptom at baseline (diarrhea, flushing, or diarrhea+flushing). The primary outcome was symptom response at month 6. Other outcomes included tumor response, safety and progression-free survival (PFS).

Results: The study was terminated after an interim analysis suggesting futility for symptom response. Baseline characteristics of the patients enrolled in the P (n=53) and O (n=57) arms were well balanced. Primary tumor location was mainly the small intestine (P, 72%; O, 81%). Numbers of patients with symptom response at month 6 were 9/43 (21%) with P and 12/45 (27%) with O (OR=0.73; 95% CI, 0.27-1.97; P=0.53). Symptom response rates overall and by stratum for each drug are tabulated. Hyperglycemia (13% vs. 2%), diarrhea (11% vs. 7%), and abdominal pain (6% vs. 9%) were the most common grade 3/4 adverse events (AEs) in the P versus O arms, and 9 (17%) and 4 (7%) patients discontinued due to AEs. Median investigator-assessed PFS, an exploratory end point, was 11.8 months with P and 6.8 months with O (HR=0.46; P=0.045).
**Conclusions**: Except for the higher frequency of hyperglycemia seen with P, both drugs had similar safety profiles. P-treated patients had longer PFS (by 5 months) than O-treated patients, despite no differences in symptom response rates. These results warrant a phase 3 trial to evaluate the therapeutic potential of P in NET.

<table>
<thead>
<tr>
<th>Stratum</th>
<th>Pasireotide LAR n^a/N^b (%) (95% exact CI)</th>
<th>Octreotide LAR n^a/N^b (%) (95% exact CI)</th>
<th>Between-Treatment OR (95%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea + flushing</td>
<td>5/37 (13.5) (4.5-28.8)</td>
<td>11/39 (28.2) (15.0-44.9)</td>
<td>0.40 (0.12-1.29)</td>
</tr>
<tr>
<td>Predominantly diarrhea</td>
<td>2/2 (100) (15.8-100)</td>
<td>1/5 (20.0) (0.5-71.6)</td>
<td></td>
</tr>
<tr>
<td>Predominantly Flushing</td>
<td>2/4 (50.0) (6.8-93.2)</td>
<td>0/1 (0) (0.0-97.5)</td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>9/43 (20.9) (10.0-36.0)</td>
<td>12/45 (26.7) (14.6-41.9)</td>
<td>0.73 (0.27-1.97)</td>
</tr>
</tbody>
</table>

CI, confidence interval; OR, odds ratio. ^aNumber of responders; ^bNumber of patients analyzed.

*Supported by Novartis Pharmaceuticals Corporation.*